Literature DB >> 18593943

The humoral immune system has a key prognostic impact in node-negative breast cancer.

Marcus Schmidt1, Daniel Böhm, Christian von Törne, Eric Steiner, Alexander Puhl, Henryk Pilch, Hans-Anton Lehr, Jan G Hengstler, Heinz Kölbl, Mathias Gehrmann.   

Abstract

Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with principal component analysis. Distinct patterns led to the hypothesis of a prognostic role of the immune system in tumors with high expression of proliferation-associated genes. In multivariate Cox regression analysis, the proliferation metagene showed a significant association with metastasis-free survival of the whole discovery cohort [hazard ratio (HR), 2.20; 95% confidence interval (95% CI), 1.40-3.46]. The B-cell metagene showed additional independent prognostic information in carcinomas with high proliferative activity (HR, 0.66; 95% CI, 0.46-0.97). A prognostic influence of the B-cell metagene was independently confirmed by multivariate analysis in a first validation cohort enriched for high-grade tumors (n = 286; HR, 0.78; 95% CI, 0.62-0.98) and a second validation cohort enriched for younger patients (n = 302; HR, 0.83; 95% CI, 0.7-0.97). Thus, we could show in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast.

Entities:  

Mesh:

Year:  2008        PMID: 18593943     DOI: 10.1158/0008-5472.CAN-07-5206

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  387 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

Review 3.  Breast cancer assessment tools and optimizing adjuvant therapy.

Authors:  Catherine Oakman; Libero Santarpia; Angelo Di Leo
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

4.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

5.  Generalized random set framework for functional enrichment analysis using primary genomics datasets.

Authors:  Johannes M Freudenberg; Siva Sivaganesan; Mukta Phatak; Kaustubh Shinde; Mario Medvedovic
Journal:  Bioinformatics       Date:  2010-10-22       Impact factor: 6.937

6.  Integrated cross-species transcriptional network analysis of metastatic susceptibility.

Authors:  Ying Hu; Gang Wu; Michael Rusch; Luanne Lukes; Kenneth H Buetow; Jinghui Zhang; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

7.  Node-Negative Breast Cancer: Which Patients Should Be Treated?

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

8.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 9.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 10.  High-throughput gene expression and mutation profiling: current methods and future perspectives.

Authors:  Thomas Karn
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.